John Morton: The State of Obesity Treatment

Howie and Harlan review the results of a new study testing the effects of anti-obesity medications on cardiovascular health. Then they're joined by Yale's John Morton, a leading bariatric surgeon, to discuss the state of weight-loss surgery and its long-term impact on patients' lives.

Links:

Obesity Drugs

“GLP-1 agonists: Diabetes drugs and weight loss”

“Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes”

“AMA urges insurance coverage parity for emerging obesity treatment options”

“National Coverage Determination: Treatment of Obesity”

“Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States”

“2022 Employer Health Benefits Survey: Section 10 - Plan Funding”

Bariatric Surgery

Mayo Clinic: Bariatric Surgery Overview

John Morton: “Correlating actual one-year weight loss with predicted weight loss by the MBSAQIP: bariatric surgical risk/benefit calculator”

“Outcomes of the Ontario Bariatric Network: a cohort study”

“Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery”

“Weight loss drugs and the push for Medicare coverage”

“Comparative Safety of Sleeve Gastrectomy and Gastric Bypass Up to 5 Years After Surgery in Patients With Severe Obesity”

“A Short History of Bernard Fisher’s Contributions to Randomized Clinical Trials”

“Persistent metabolic adaptation 6 years after The Biggest Loser competition”

“Eligibility for Cardiovascular Risk Reduction Therapy in the U.S. Based on SELECT Trial Criteria: Insights from the National Health and Nutrition Examination Survey”

Learn more about the MBA for Executives program at Yale SOM.

Email Howie and Harlan comments or questions.